ZS Associates
 
This week's BioPharma Dive brought to you by
 
 
 
 
 
 
U.S. and European novel first launch trends and implications for emerging pharma
 
Personalized marketing is now a commercial necessity. See why biopharma leaders are rethinking their launch playbooks from the ground up.
 
 
RECENT INSIGHTS
 
 
 
 
Why specialty drug reimbursement varies so widely
 
 
Our joint research with Turquoise Health uncovers inconsistencies in how specialty products are reimbursed, affecting access and strategy. Explore the findings >>
 
 
 
 
What’s changing for U.S. first-time launches
 
 
Novel first launches are declining and competition is rising. Here’s what that means for emerging biopharma go‑to‑market strategies. See what’s shifting >>
 
 
 
 
Optimize GTN with an integrated strategy
 
 
An end-to-end GTN strategy can align decisions across finance, access and ops. Learn how integration drives better business outcomes. Get the guide >>
 
 
 
 
Upcoming webinar: AI is modernizing incentive compensation
 
 
Join our experts and explore how to apply AI across the IC life cycle, from planning to scenario modeling to payout insights and more. Register now >>
 
 
 

zsinsights@zs.com
© 2025 ZS. All Rights Reserved.
One Rotary Center, 1560 Sherman Avenue, Evanston, Illinois 60201 USA +1 847 492 3600
 
 

Want to reach 108,000+ biopharma executives with your own message? Get the media kit or contact us directly at advertising@industrydive.com.

About this email: You are receiving this message as part of your complimentary newsletter subscription to BioPharma Dive. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. BioPharma Dive is a product of TechTarget, Inc. and its subsidiaries, 275 Grove St. Newton, MA, 02466